Dexketoprofen

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dexketoprofen
Dexketoprofen.png
Dexketoprofen ball-and-stick.png
Systematic (IUPAC) name
(2S)-2-[3-(benzoyl)phenyl]propanoic acid
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
Identifiers
ATC code M01AE17
PubChem CID 667550
ChemSpider 580922 N
UNII 6KD9E78X68 YesY
KEGG D07269 YesY
ChEBI CHEBI:76128 N
ChEMBL CHEMBL75435 N
Chemical data
Formula C16H14O3 
Mol. mass 254.28056 g/mol
 N (what is this?)  (verify)

Dexketoprofen is a non-steroidal anti-inflammatory drug. It is manufactured by Menarini, under the tradename Keral. It is available in the UK, as dexketoprofen trometamol, as a prescription-only drug and in Latin America as Enantyum, produced by Menarini. Also, in Italy and Spain it is available as an over the counter-drug under the tradename respectively Enantyum, Ketesgel. Both in Lithuania and Estonia it is available as over the counter-drug under tradename Dolmen.[1] In Mexico it is available in tablet form as "Stadium" made by Menarini in Luxemburg.

Indications[edit]

Short-term treatment of mild to moderate pain, including dysmenorrhoea.

Pharmacology[edit]

Dexketoprofen belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with Peripheral analgesic action it possesses central analgesic action.

Warning[edit]

  1. This medicine may cause dizziness and so may affect your ability to drive or operate machinery safely. Do not drive or operate machinery until you know how this medicine affects you and you are sure it won't affect your performance.
  2. This medicine is not for long term use

Use with caution in[edit]

  1. Decreased heart function
  2. Disorders involving the formation of blood cells (haematopoietic disorders)
  3. Elderly people
  4. Excess retention of water in the body tissues (fluid retention)
  5. History of allergies
  6. Long-term inflammation of skin and some internal organs (systemic lupus erythematosus)
  7. Low volume of circulating blood (hypovolaemia)
  8. Mild to moderately decreased liver function
  9. Mildly decreased kidney function
  10. Syndrome with symptoms of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon (mixed connective tissue disease)

Not to be used in[edit]

  1. Active bleeding
  2. Allergy to any of its ingredients
  3. Allergy to aspirin or other medicines in this class
  4. Asthma or history of asthma
  5. Bleeding disorders
  6. Bleeding from the stomach or intestines
  7. Breastfeeding
  8. Children
  9. Crohn's disease
  10. History of stomach or duodenal ulcers or indigestion
  11. Inflammation of the bowel and back passage
  12. Inherited tendency to bleed (haemorrhagic diathesis)
  13. Moderate to severely decreased kidney function
  14. Peptic ulcers
  15. Pregnancy
  16. Severe heart failure
  17. Severely decreased liver function

Dose[edit]

In the USA: Adult: 12.5 mg of ketoprofen every 4–6 hours as needed, or 25 mg every 8 hours as needed; max 75 mg daily. Elderly: initially max 50 mg daily as needed. Child: not recommended.

In Europe: As prescribed, the dosage is variable being consistent with the nature, severity and duration of the pain episode. Currently the prescribed amount is 25 mg every 8 hours, although the daily dosage should not exceed 75 mg. In elderly patients, light to moderate liver and renal failure, the maximum dosage is set at a maximum of 50 mg/24h. Dexketoprofen is currently not prescribed to children under the age of 18.

Citations[edit]

[1][dead link]

References[edit]

  1. ^ "Medicinal products authorised in Estonia". State Agency of Medicine. 22 May 2014. Retrieved 23 May 2014.